PET+10 Study: Efficacy of Platin/Etoposide Combination in Well-Differentiated Pancreatic Neuroendocrine Tumors with Ki-67 ≥ 10%

#916

Introduction: Platin-etoposide (PE), the gold standard regimen for poorly differentiated neuroendocrine carcinomas, might be effective in well-differentiated pancreatic neuroendocrine tumors (WD-PNETs) with a high Ki-67 proliferation index.

Aim(s): To compare the efficacy of PE to other regimens, especially doxorubicin/streptozocin (D-STZ) in patients with Ki-67 ≥ 10%.

Materials and methods: Retrospective, multicenter study, within the French study group of endocrine tumors (GTE). All patients with proven WD-PNETs and Ki-67 ≥ 10% treated by chemotherapy between 2000 and 2012 were included. Survival curves (progression-free survival: PFS and overall survival: OS) were estimated by the Kaplan-Meier method and compared using log-rank tests (PE v. other regimens).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: BAUDIN E

Authors: Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S,

Keywords: platin/etoposide, pNETs, Ki-67,